14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
ANRO vs ICCC: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Alto Neuroscience Inc. (ANRO) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ANRO carries a Unified Composite Score of 29.2/100 (SELL) at $27.12 (N/M Forward P/E, 0.0% operating margin), whereas ICCC carries 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin).
Technical & Structure Timing Caution: ANRO is currently in a Breakdown options structure phase (RSI 54.3); meanwhile ICCC trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ANRO vs ICCC. Trailing 12-month operating profitability (ANRO 0.0% vs ICCC 15.2%) and valuation multiples (ANRO N/M vs ICCC N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $97.7M market capitalization and 15.2% operating margin.
OpEx & R&D Reinvestment25.1% of Rev ($17M)
90D Engineering Disclosures0 Published
Investor FAQ ANRO vs ICCC Key Questions & Quantitative Answers
As of Nov 16, 2026, Immucell Corp (ICCC) is the stronger overall head-to-head candidate over Alto Neuroscience Inc. (ANRO) in the Tradestie Institutional Equity Comparison Engine, winning 8–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ANRO carries a Unified Composite Score of 29.2/100 (SELL) at $27.12 (N/M Forward P/E, 0.0% operating margin), whereas ICCC carries 43.8/100 (HOLD) at $11.42 (N/M Forward P/E, 15.2% operating margin). Technical & Structure Timing Caution: ANRO is currently in a Breakdown options structure phase (RSI 54.3); meanwhile ICCC trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 67.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ICCC leads the Growth & Scale pillar: ANRO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ICCC at +11.5% YoY revenue growth and +259.9% YoY earnings growth on $67M TTM revenue (40.3% gross margin, 15.2% operating margin). On trailing 12-month operating scale, ANRO generates N/A in USD-normalized revenue versus $67M for ICCC. In operating R&D and SG&A reinvestment, ANRO deploys N/A (0 90-day corporate R&D disclosures) versus 25.1% of Rev ($17M) (0 disclosures) for ICCC.
ICCC screens cheaper on headline valuation multiples. ANRO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ICCC trades at N/M Forward P/E, 56.6x Trailing P/E, N/M PEG, and 1.6x EV/Revenue (11.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ANRO (-46.7% ROE) versus ICCC (2.6% ROE) capital efficiency.
In options market volatility and institutional positioning, ANRO carries 79.4% implied volatility (8th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.95β · 90% Vol realized risk). By comparison, ICCC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.24β · 46% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.